None
Quote | Alterity Therapeutics Limited (NYSE:ATHE)
Last: | $ |
---|---|
Change Percent: | -5.61% |
Open: | $0.77 |
Close: | $0.7113 |
High: | $0.7763 |
Low: | $0.7011 |
Volume: | 35,028 |
Last Trade Date Time: | 02/12/2020 04:41:14 pm |
News | Alterity Therapeutics Limited (NYSE:ATHE)
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month Data from bioMUSE ...
2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...
Message Board Posts | Alterity Therapeutics Limited (NYSE:ATHE)
Subject | By | Source | When |
---|---|---|---|
she will soon enough my friend! athe volume | NYCJR | investorshub | 07/18/2022 9:56:04 PM |
soo oversold its not even funny, also float | NYCJR | investorshub | 07/18/2022 4:14:36 PM |
more news should be coming in the next | NYCJR | investorshub | 07/18/2022 4:14:03 PM |
remember folks, this ran hard around this time | NYCJR | investorshub | 07/18/2022 4:13:25 PM |
building myself a nice little position here folks! | NYCJR | investorshub | 07/16/2022 1:02:13 AM |
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson's Disease – – ATH434-201 Phase 2 Baseline Data...
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month Data from bioMUSE ...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...